Careers
Trial Participants
Investigator Login
Choose Language
Search

Scientific Expertise

Scientific Expertise >

By Therapeutic or Specialty Areas

By Therapeutic or Specialty Areas >
Cardiovascular Cell & Gene Therapies Dermatology Diabetes and Endocrinology Hepatology Infectious Disease Inflammation Nephrology Neuroscience Oncology Ophthalmology Pediatrics Rare Disease and Orphan Drugs Respiratory & Pulmonary Rheumatoid Arthritis

By Molecule

By Molecule >
Global Solutions

Global Solutions >

Clinical Development

Clinical Development >
Early: Phase I / IIa Late: Phase IIb / III Real-World Evidence and Post-Approval Studies Decentralized Clinical Trials Data Analysis & Reporting Clinical Trial Project Management & Monitoring Patient Safety & Pharmacovigilance

Clinical Pharmacology

Clinical Pharmacology >

Drug Development Consulting Services

Drug Development Consulting Services >
Market Access & HEOR Strategy

Enabling Technologies

Enabling Technologies >
Mobile Clinical Services

Full and Functional Service Provider Models

Full and Functional Service Provider Models >

Patient Access

Patient Access >

Device and Diagnostic Development

Device and Diagnostic Development >
Our Customers

Our Customers >

Pharmaceutical

Pharmaceutical >

Biotechnology

Biotechnology >

Med Tech

Med Tech >
About Us

About Us >

Leadership

Leadership >

Newsroom

Newsroom >

Locations

Locations >

Contact Us

Back

Search

Quick Links

Scientific Expertise
Global Solutions
Our Customers
About Us

Resources

Careers
Trial Participants
Investigator Login
Contact Us

Legal

Terms and Conditions
Privacy Policy
California & Virginia Privacy Policy
Combatting Modern Slavery & Human Trafficking Statement
Non-Discrimination Policy

Fortrea is the new brand identity for Labcorp's Clinical Development and Commercialization business in connection with the spin-off from Labcorp, which is expected in mid-2023. Fortrea's spin-off from Labcorp is subject to the satisfaction of certain customary conditions, including, among others, the receipt of final approval by Labcorp’s Board of Directors, the receipt of appropriate assurances regarding the tax-free nature of the separation and effectiveness of any required filings with the Securities and Exchange Commission. There can be no assurances regarding the ultimate timing of the transaction or that the spin-off will be completed. Until the spin-off is complete, Fortrea's products, services and offerings are still owned and operated by Labcorp. Ⓒ 2023 Copyright Fortrea Inc. All Rights Reserved.